Adawi Kamal
Adawi Kamal, CFO, reported an open-market or private sale at FATE THERAPEUTICS INC involving 6582.000000 shares for an estimated $13524.69. Reported holdings after the transaction were 93418.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
- Trade date
- Nov 03, 2026
- Filing date
- Nov 04, 2026
How reported position traded is calculated
Shares sold ÷ (holdings after + shares sold). Estimated position before: 100,000 shares.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
FATE price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- Sell Code S
- Identifier
- 0001193125-26-447171 Common Stock
- Transaction date
- Nov 03, 2026 Filed Nov 04, 2026, 09:01 PM · 1d delay
- Shares
- 6,582 sh $2.05 per share
- Estimated value
- -$13.5k Computed from shares × price
- Holdings after
- 93,418 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
+10 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - timely_filing+4 points
reporting_delay_days = 1
Filing reported within two business days of the transaction.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
Chief Financial Officer
- F1
Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 18,750 shares of Common Stock underlying RSUs granted to the Reporting Per…
- F2
Represents the weighted average sale price of the shares sold ranging from $2.020 to $2.084 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a securit…
0 other transactions
0 recent txs